A novel injectable water-soluble amphotericin B-arabinogalactan conjugate

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 8, 1999, Pages 1975-1981

  Falk, Rama ^a   Domb, Abraham J ^b   Polacheck, Itzhack ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; ARABINOGALACTAN;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CHEMICAL REACTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; YEAST CELL;

EID: 0032819384     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.8.1975     Document Type: Article

References (28)

1. Adams, M. F., and C. Douglas. 1963. Arabinogalactan - a review of the literature. TAPPI J. 46:544-558.
2. Andrews, F. A., W. H. Beggs, and G. Sarosi. 1977. Influence of antioxidants on the bioactivity of amphotericin B. Antimicrob. Agents Chemother. 11:615-618.
3. Bodey, G. P. 1977. Infectious complications in the cancer patient. Curr. Probl. Cancer 1:1-63.
4. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:512-531.
5. Brajtburg, J., S. Elberg, S. J. Travis, and G. S. Kobayashi. 1994. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Antimicrob. Agents Chemother. 38:294-299.
6. Buler, W. T. 1966. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B. JAMA 195:127-131.
7. Chabot, G. G., R. Pazdur, F. A. Valeriote, and L. H. Baker. 1989. Pharmacokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 78:307-310.
8. Denning, D. W. 1991. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J. Antimicrob. Chemother. 28(Suppl. B):1-16.
9. Domb, A. J., G. Linden, I. Polacheck, and S. Benita. 1996. Nystatin-dextran conjugates: synthesis and characterization. J. Polymer Sci. 34:1229-1236.
10. Foster, D., C. Washington, and S. S. Davis. 1988. Toxicity of solubilized and colloidal amphotericin B formulation to human erythrocytes. J. Pharm. Pharmacol. 40:325-328.
11. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
12. Graybill, J. R., P. C. Craven, R. L. Taylor, D. M. Williams, and W. E. Magee. 1982. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145:748-752.
13. Gubbins, P. O., J. L. Bowman, and S. R. Penzak. 1998. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients. Pharmacotherapy 18:549-564.
14. Hay, R. J. 1994. Liposomal amphotericin B, AmBisome. J. Infect. 1:35-43.
15. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-S144.
16. Hostetler, J. S., K. V. Clemons, L. H. Hanson, and D. A. Stevens. 1992. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36:2556-2560.
17. Larsen, C. 1990. Dextran products, Physico-chemical and chemical aspects in relation to in vivo properties. Ph.D. dissertation. Villadsen and Christensen, Copenhagen, Denmark.
18. Levy, M. Y., I. Polacheck, Y. Barenholz, and S. Benita. 1993. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis. J. Med. Vet. Mycol. 31:202-218.
19. Lindenbaum, G., O. Mirgorodskaya, B. Moskvichev, and I. Tereshin. 1977. Study of some physicochemical and enzyme properties of polymer derivatives of terrilytin on the basis of dextran. Khim.-Pharm. Zh. 11:81-86.
20. Maddux, M. S., and S. L. Barriere. 1980. A review of complications of amphotericin B therapy: recommendation for prevention and management. Drug Intel. Clin. Pharm. 14:177-181.
21. Maeda, M., C. Nishimura, D. Umeno, and M. Takagi. 1994. Psoralen-containing vinyl monomers for conjugation of double-helical DNA with vinyl polymers. Bioconj. Chem. 5:527-531.
22. Merz, W. G., J. E. Karp, M. Hoagland, M. Jett-Goheen, J. M. Junkins, and A. F. Hood. 1988. Diagnosis and successful treatment of fusariosis in the compromised host. J. Infect. Dis. 158:1046-1055.
23. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Odds, F. C. 1988. Candida and candidosis, 2nd ed. Bailliere Tindall, London, United Kingdom.
25. Sabra, R., and R. A. Branch. 1990. Amphotericin B nephrotoxicity. Drug Safety 5:94-108.
26. Stevens, D. A. 1994. Overview of amphotericin B colloidal dispersion (Amphocil). J. Infect. 28(Suppl. 1):45-49.
27. van Etten, E. W. M., C. van den Heuvel de Groot, and I. A. Bakker-Woudenberg. 1993. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J. Antimicrob. Chemother. 32:723-739.
28. Zar, J. H. 1984. Testing for goodness of fit, p. 40-60. In Biostatistical analysis. Prentice-Hall, Englewood Cliffs, N.J.